Significance of a Single CA 125 Assay Combined with Ultrasound in the Early Detection of Ovarian and Endometrial Cancer

Vuento, Maarit; Stenman, Ulf‐Hǎkan; Pirhonen, Jouko; Mäkinen, Juha; Laippala, Pékka; Salmi, Tuula

doi:10.1006/gyno.1996.4545

Cited by 35 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although CA125 is routinely used in some practices, it has poor sensitivity and specificity [15][16][17][18]. Only 10-20% of patients with early stage endometrial cancer and approximately 25% of patients with asymptomatic recurrent disease have an elevated CA125 level [19,20].…”

Section: Introductionmentioning

confidence: 99%

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Dobrzycka

Maćkowiak-Matejczyk²,

Terlikowska

et al. 2016

Advances in Medical Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Dobrzycka

Maćkowiak-Matejczyk²,

Terlikowska

et al. 2016

Advances in Medical Sciences

View full text Add to dashboard Cite

“…At the present time, the detection of recurrent disease is through monitoring for clinical symptoms and the use of imaging modalities, which normally detect disease in advanced stages. Elevated CA-125 levels have been demonstrated to correlate with advanced disease (4)(5)(6)(7)(8), however, the use of CA125 for the detection of early recurrent endometrial cancer is limited. Only 10% to 20% of patients with early stage disease and approximately 25% of patients with asymptomatic recurrent disease will have an elevated CA125 level (9;10).…”

Section: Introductionmentioning

confidence: 99%

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

Moore

Brown

Miller

et al. 2008

Gynecologic Oncology

194

143

View full text Add to dashboard Cite

Objective-Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease. Currently, the tumor maker CA125 is utilized in this role with limited value. The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.Methods-Preoperative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125. Control samples were obtained from healthy postmenopausal women. Logistic regression models and receiver operating characteristic (ROC) curves were constructed for each tumor marker and for all combinations, with cross-validation analyses to obtain average sensitivities at set specificities of 90%, 95%, and 98%.Results-Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed. At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125. For stage I disease, HE4 yielded a 17.1% improvement in sensitivity compared with CA125.

show abstract

“…A single CA 125 determination provides no advance in the early detection of endometrial as well as ovarian carcinoma in asymptomatic postmenopausal women compared to transvaginal ultrasonography. The vast majority of women with an elevated CA 125 value have some reason other than an ovarian or endometrial malignancy for this finding [13].…”

Section: Ca 125mentioning

confidence: 92%

The Value of Tumor Markers in Endometrial Carcinoma: Review of Literature

Yaşa¹,

Takmaz²,

Dural³

et al. 2013

JCT

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecologic malignancy in more developed countries. Most endometrial carcinomas cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15% -20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. Although it has a comparatively low mortality rate compared with other gynaecological cancers, it is capable of aggressive behaviour. Diagnosis at an early stage is the most important determinant of survival. Discovery of new diagnostic biomarkers/panels for early diagnosis of endometrial cancer is one of the main challenges of modern medicine. For endometrial cancers, there are no established serum markers. We will review the present knowledge regarding tumor markers, assessing how such markers could be applied to address in screening, diagnosis and monitoring of endometrial carcinoma.

show abstract

Significance of a Single CA 125 Assay Combined with Ultrasound in the Early Detection of Ovarian and Endometrial Cancer

Cited by 35 publications

References 0 publications

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

The Value of Tumor Markers in Endometrial Carcinoma: Review of Literature

Contact Info

Product

Resources

About